banner

ALR Technologies Partners with Mid-America Coalition in Bid to Commercialize Diabetes Management Program

ALR Technologies (ALRT)

ALR Technologies Inc. (OTCBB: ALRT) took a big step in the direction of commercializing their Health-e-Connect Diabetes Management Program with news this week that the company has partnered with the Mid-America Coalition on Health Care, or MACHC.  The new pact means that MACHC will be introducing the ALRT program for pilot participation by its membership, which consists of 67 organizations representing more than 500,000 employees in the greater Kansas City area.

Cumulatively, the Health-e-Connect Program is a robust and comprehensive remote diabetes management platform featuring ALRT’s FDA-cleared and HIPAA-compliant Health-e-Connect system, Diabetes Care Facilitators, software and hardware that is compatible with all of the major glucose meters.  It’s a complete monitoring solution to help clinicians, patients and caregivers to efficiently manage diabetes outcomes.  For care plans, the system assists in meeting HEDIS (Healthcare Effectiveness Data and Information Set) goals.

According to NCQA, HEDIS “is a tool used by more than 90 percent of America’s health plans to measure performance on important dimensions of care and service.”  Clearly, it is an important dimension to health plans and systems, such as the Health-e-Connect program, could prove invaluable in optimizing performance.

“The goal of the partnership is to assist their multi-stakeholder membership, some of which are the largest employers in the Kansas City area, better manage and reduce the costs for their employees living with diabetes,” the Richmond, Virginia-based company said in a statement on Wednesday.



MACHC President and CEO Troy Ross commented, “Throughout our 33 year history, our mission is focused on identifying and offering solutions that improve the way health care is designed and delivered so that our members can better manage their healthcare costs. The Health-e-Connect Program is an innovative tool that aligns with our mission to provide solutions that improve quality and lower the costs of expensive chronic diseases such as diabetes.”

In recent months, activity seems to be bustling at ALR Technologies.  The company has substantially strengthened its team with additions such as Certified Diabetes Educator Dr. Kent Stoneking, as Director, Diabetes Care Facilitation.  Dr. Stoneking is an affiliate member of the American Diabetes Association and the American Pharmacists Association.  ALRT has also added Jerome Hickey, a former National Account Manager at Medicis Pharmaceutical Company and Director of Managed Markets Training at Pfizer, Inc. (NYSE: PFE).

William Smith has also joined ALR Technologies as Chief Commercial Officer and board member.  Smith has a distinguished history the could open many doors for the company’s initiatives, including serving for a decade as Vice President of U.S. Public Affairs and Policy at Pfizer, before moving on to Managing Director at NSI, LLC, a Washington, D.C.-based consulting firm where he advised major pharmaceutical, biotechnology and medical device companies including AstraZeneca (NYSE: AZN), Merck (NYSE: MRK) and Genzyme, before it was bought by Sanofi (NYSE: SNY) for over $20 million in 2011.

Late in the third quarter, the company also added consulting and marketing guru Ken Robulak and Dr. Alfonso Salas to its board.  Dr. Salas has deep roots in the Columbian markets, a significant area of opportunity for ALRT to broaden its sales channels.

Bottom line is the company has openly communicated its strategic plans to bring the Health-e-Connect to market and, judging by the corporate activity, that goal is drawing closer to meaningful revenue.  The company has said that it was immersed in negotiations and this new partnership with MACHC could be the first glimpse at the large-scale potential that ALRT has offer with their technology.

ALR Technologies (ALRT) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated three thousand dollars for one month of consultation and journalism services and to manage an investor relations/awareness program by ALR Technologies. Viper has completed prior service agreements with ALRT Technologies with full disclosure listed on our disclaimer/disclosure page. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

0 comments

Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Stocks Mixed on Monday

Stocks Mixed on Monday(0)

The Dow Jones industrial average topped 16,000 for the first time ever Monday, while the S&P 500 briefly surpassed 1,800. The Dow retreated from the 16,000 level, but still gained 14.32 points from Friday”s all-time high close, to 15,976. The S&P 500 index dipped 6.65 points to 1,791.53. The NASDAQ fell 36.90 points to 3,949.07

Cellceutix Targeting Gram-Negative and Candida Fungal Infections

Cellceutix Targeting Gram-Negative and Candida Fungal Infections(0)

Monday morning, Cellceutix Corp. (OTCQB: CTIX) provided shareholders with an update on its progress with filing an Investigational New Drug application with the FDA for its anti-psoriasis drug. Additionally – and taking the headline – the company delivered to shareholders news that it has made additional promising advancements with its pipeline to potentially address diseases

Catalyst Pharmaceutical Partners Stock Chart Analysis Video

Catalyst Pharmaceutical Partners Stock Chart Analysis Video(0)

The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be

EnteroMedics Stock Chart Analysis Video

EnteroMedics Stock Chart Analysis Video(0)

The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel. EnteroMedics is a medical device

NXT-ID Authentication Using Face and Voice Recognition

NXT-ID Authentication Using Face and Voice Recognition(0)

There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and

read more
banner

Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.